{"paper_id":"1ddb5422-952a-44d3-a543-6b2cc65cc2de","body_text":"Abstract\nUterine adenomyosis is a chronic disease that affects women of childbearing age from years to decades. Conservative surgeries are difficult to perform, and the lesions are prone to recurrence after surgery. They require long-term management. As one of the important issues of long-term management, drug therapy is useful and has effects on controlling symptoms, delaying the progress of the disease, and preventing recurrence. According to the different mechanisms of action, the indications for medication should be understood, used alone or in combination with surgical treatment and integrated traditional Chinese and western medicine. While taking a medication, attention should be paid to the side effects, and evaluate the progress of the adenomyosis. Therefore drug treatment and regular follow-up monitoring are important strategies. In this chapter, the mechanisms and side effects of common drug treatments for adenomyosis are introduced one by one.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nHauksson A, Ekström P, Juchnicka E, Laudanski T, Åkerlund M, Mats Åkerlund D. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand. 1989;68(1):31–4.\nLi L, Leng JH, Dai Y, Zhang JJ, Jia SZ, Li XY, Shi JH, Zhang JR, Li T, Xu XX, Liu ZZ, You SS, Chang XY, Lang JH. The study LNG-IUS in the management of menorrhagia due to adenomyosis. Chinese Journal of Obstetrics and Gynecology. 2016;006:424–30.\nLi L, Leng JH, Shi JH, Zhang JJ, Jia SZ, Li XY, Dai Y, Zhang JR, Li T, Xu XX. A prospective study of LNG-IUS for the treatment of severe dysmenorrhoea associated with adenomyosis. Chinese Journal of Obstetrics and Gynecology. 2016;005:345–51.\nLin CJ, Hsu TF, Chang YH, Huang BS, Jiang LY, Wang PH, Chen YJ. Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma. Taiwanese journal of obstetrics & gynecology. 2018;57(1):47–51.\nYoum J, Lee HJ, Kim SK, Kim H, Jee BC. Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system. Int J Gynecol Obstet. 2014;126(2):165–9.\nLi L, Leng JH, Jia SZ, Zhang JJ, Li XY, Shi JH. Analysis of the factors associated with unplanned removal and shedding of LNG-IUS in uterus with adenomyosis. Chinese Journal of Practical Gynecology and Obstetrics. 2016;32(11):1088–92.\nBackman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol. 2002;99(4):0–613.\nAndres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523–9. Epub 2015/03/10. https://doi.org/10.1007/s00404-015-3681-6.\nOsuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril. 2017;108(4):673–8.\nNeriishi K, Hirata T, Fukuda S, Izumi G, Nakazawa A, Yamamoto N, Harada M, Hirota Y, Koga K, Wada-Hiraike O. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res. 2018;44(8):1439–44.\nYu Q, Zhang S, Li H, Wang P, Zvolanek M, Ren X, Dong L, Lang J. Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study. Journal of women’s health (Larchmt). 2019;28(2):170–7. Epub 2018/11/22. https://doi.org/10.1089/jwh.2018.7084. PubMed PMID: 30461337.\nChe X, Wang J, He J, Yu Q, Sun W, Chen S, Zou G, Li T, Guo X, Zhang X. A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2019. Epub 2019/12/10; https://doi.org/10.1111/jcmm.14866.\nMatsushima T, Akira S, Fukami T, Yoneyama K, Gynecology TTJ, Therapy MI. Efficacy of hormonal therapies for decreasing uterine volume in patients with Adenomyosis. Gynecol Minim Invasive Ther. 2018;7(3):119.\nWu D, Hu M, Hong L, Hong S, Ding W, Min J, Fang G, Guo W. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet. 2014;290(3):513–23.\nYang X, Huang R, Wang Y-f, Liang X-y. Pituitary suppression before frozen embryo transfer is beneficial for patients suffering from idiopathic repeated implantation failure. J Huazhong Univ Sci Tech. 2016;36(1):127–31. https://doi.org/10.1007/s11596-016-1554-2.\nBadawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(4):489–95.\nPeng C, Zhou YF. A new exploration of the drug therapy of uterine adenopathy. China Family Planning and Obstetrics and Gynecology. 2019(4):18–20.\nDuan H, Wang S, Hao M, Chen L, Tang J, Wang X, Peng YX, Zhang SC, Cao L, Yu JJ. Research of gestrinone-related abnormal uterine bleeding and the intervention in the treatment:a multi-center, randomized, controlled clinical trial. Chinese Journal of Obstetrics and Gynecology. 2016;2:98–102.\nOladosu FA, Tu FF, Hellman KM. Non-steroidal anti-inflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol. 2018;218(4):390–400. https://doi.org/10.1016/j.ajog.2017.08.108.\nWang LD, Leng JH, Zhang F, Li YN, Sun MX, Shi W, Xu L. Analysis and research on the law of chinese medicine for the treatment of uterine adenopathy based on the auxiliary platform of Traditional Chinese medicine. Shi Chen National Medcine 2018;29(3):742–4.\nJin Y, Liu ZK. Clinical observation of Traditional Chinese medicine enema for the treatment of adenomyosis. Journal of Practical Gynecologic Endocrinology 2019;6(2):72–7.\nLiu AX, Huang WH, Lai CY. Acupuncture combined with Chinese medicine to treat 30 cases of uterine adenomyosis. Chinese Acupuncture & Moxibustion. 2018;38(6):655–6.\nRocha TP, Andres MP, Borrelli GM, Abrão MS. Fertility-sparing treatment of adenomyosis in patients with infertility: a systematic review of current options. Reprod Sci. 2018;25(4):480–6.\nYe MZ Deng XL, Zhu XG, Xue M. High-intensity focused ultrasound ablation combined GnRH-a and LNG-IUS in the treatment of uterine adenomyosis. Chinese Journal of Obstetrics and Gynecology. 2016;51(9):643–9.\nZhu L, Chen S, Che X, Xu P, Huang X, Zhang X. Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy: a long-term result in a single institution. J Pain Res. 2019;12:1917.\nGuo Q, Xu F, Ding Z, Li P, Wang X, Gao B. High intensity focused ultrasound treatment of adenomyosis: a comparative study. Int J Hyperth. 2018;35(1):505–9.\nMingzhu Y,Xinliang D, Xiaogang Z, Min X. High-intensity focused ultrasound ablation combined GnRH-a and LNG-IUS in the treatment of uterine adenomyosis. Chinese J Obstet Gynecol. 2016;\nYe MZ, Xue M. Application of high-intensity focused ultrasound in the treatment of uterine adenopathy. Chinese Journal of Practical Gynaecology and Obstetrics. 2019;35(5):522–7.\nAuthor information\nAuthors and Affiliations\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.\nAbout this chapter\nCite this chapter\nShi, J., Dai, Y., Leng, J. (2021). The Medical Treatment of Adenomyosis. In: Xue, M., Leng, J., Wong, F. (eds) Adenomyosis. Springer, Singapore. https://doi.org/10.1007/978-981-33-4095-4_10\nDownload citation\nDOI: https://doi.org/10.1007/978-981-33-4095-4_10\nPublished:\nPublisher Name: Springer, Singapore\nPrint ISBN: 978-981-33-4094-7\nOnline ISBN: 978-981-33-4095-4\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}